OBJECTIVES: Massachusetts was among the first states to allow standing orders to facilitate pharmacy-based naloxone purchases and reduce opioid overdose deaths. We conducted a unique purchase trial to establish a valid measure of standing order naloxone in Massachusetts, using purchasers from 2 high priority populations to determine whether naloxone is less accessible to those who use illicit opioids than other potential purchasers. DESIGN: Purchase trial. SETTING AND PARTICIPANTS: The study used a stratified random sample of 200 chain and independent retail pharmacies across Massachusetts. Each pharmacy underwent 2 purchase attempts-1 by a person who used illicit opioids (PWUIO) and 1 by a potential bystander who did not use illicit opioids but had a relationship with someone at risk of opioid overdose. OUTCOME MEASURE: Successful or unsuccessful naloxone purchase attempt. RESULTS: Overall, 322 of 397 purchase attempts (81%) were successful, with no statistically significant difference between PWUIO and bystanders (P = 0.221). Most purchases (93%) resulted in the acquisition of single-step nasal naloxone (Narcan; median cost $133.38). Forty percent of the purchases included state-mandated verbal counseling, and PWUIO were significantly less likely to receive counseling than bystanders (30% vs. 51%, P < 0.001). Common reasons for failed purchase were not stocking naloxone (47%), price > $150 (25%), and requiring a prescription (15%). Chain pharmacies were significantly more likely to sell naloxone than independent pharmacies (86% vs. 53%, P < 0.001). CONCLUSION: We documented high levels of naloxone access for both PWUIO and bystanders, suggesting Massachusetts could serve as a model for states seeking to improve pharmacy-based naloxone access. Additional implementation efforts should focus on expanding availability at independent pharmacies and supporting pharmacies in proactively offering naloxone to PWUIO and other high-risk individuals.
OBJECTIVES: Massachusetts was among the first states to allow standing orders to facilitate pharmacy-based naloxone purchases and reduce opioid overdose deaths. We conducted a unique purchase trial to establish a valid measure of standing order naloxone in Massachusetts, using purchasers from 2 high priority populations to determine whether naloxone is less accessible to those who use illicit opioids than other potential purchasers. DESIGN: Purchase trial. SETTING AND PARTICIPANTS: The study used a stratified random sample of 200 chain and independent retail pharmacies across Massachusetts. Each pharmacy underwent 2 purchase attempts-1 by a person who used illicit opioids (PWUIO) and 1 by a potential bystander who did not use illicit opioids but had a relationship with someone at risk of opioid overdose. OUTCOME MEASURE: Successful or unsuccessful naloxone purchase attempt. RESULTS: Overall, 322 of 397 purchase attempts (81%) were successful, with no statistically significant difference between PWUIO and bystanders (P = 0.221). Most purchases (93%) resulted in the acquisition of single-step nasal naloxone (Narcan; median cost $133.38). Forty percent of the purchases included state-mandated verbal counseling, and PWUIO were significantly less likely to receive counseling than bystanders (30% vs. 51%, P < 0.001). Common reasons for failed purchase were not stocking naloxone (47%), price > $150 (25%), and requiring a prescription (15%). Chain pharmacies were significantly more likely to sell naloxone than independent pharmacies (86% vs. 53%, P < 0.001). CONCLUSION: We documented high levels of naloxone access for both PWUIO and bystanders, suggesting Massachusetts could serve as a model for states seeking to improve pharmacy-based naloxone access. Additional implementation efforts should focus on expanding availability at independent pharmacies and supporting pharmacies in proactively offering naloxone to PWUIO and other high-risk individuals.
Authors: Maya Doe-Simkins; Emily Quinn; Ziming Xuan; Amy Sorensen-Alawad; Holly Hackman; Al Ozonoff; Alexander Y Walley Journal: BMC Public Health Date: 2014-04-01 Impact factor: 3.295
Authors: Robin A Pollini; Susannah Slocum; Jenny Ozga; Rebecca Joyce; Ziming Xuan; Traci C Green; Alexander Y Walley Journal: J Am Pharm Assoc (2003) Date: 2021-08-23
Authors: Robin A Pollini; Jenny E Ozga; Rebecca Joyce; Ziming Xuan; Alexander Y Walley Journal: Drug Alcohol Depend Date: 2021-12-31 Impact factor: 4.492
Authors: Xiao Zang; Alexandria Macmadu; Maxwell S Krieger; Czarina N Behrends; Traci C Green; Jake R Morgan; Sean M Murphy; Shayla Nolen; Alexander Y Walley; Bruce R Schackman; Brandon Dl Marshall Journal: Int J Drug Policy Date: 2021-09-03
Authors: Robin A Pollini; Susannah Slocum; Jenny E Ozga; Rebecca Joyce; Ziming Xuan; Traci C Green; Alexander Y Walley Journal: J Am Pharm Assoc (2003) Date: 2022-03-19
Authors: Shayla Nolen; Xiao Zang; Avik Chatterjee; Czarina N Behrends; Traci C Green; Aranshi Kumar; Benjamin P Linas; Jake R Morgan; Sean M Murphy; Alexander Y Walley; Shapei Yan; Bruce R Schackman; Brandon D L Marshall Journal: Addiction Date: 2021-12-05 Impact factor: 7.256
Authors: Susannah Slocum; Jenny E Ozga; Rebecca Joyce; Alexander Y Walley; Robin A Pollini Journal: BMC Public Health Date: 2022-04-13 Impact factor: 3.295